Table 1.

Comparison of clinicopathological patient characteristics as well as TPX2 expression between the non-gemcitabine-based and the gemcitabine-based palliative treatment subgroups in the advanced PDAC cohorts.

	Treatment arm, no (%)
	Non-gemcitabine-based (n = 40)	Gemcitabine-based (n = 99)	P value (χ2)
Sex
Female	22 (55.0)	57 (57.6)	0.78
Male	18 (45.0)	42 (42.4)
Age (years)
≤60	16 (40.0)	41 (41.4)	0.88
>60	24 (60.0)	58 (58.6)
TPX2 expression
Low	36 (90.0)	84 (84.8)	0.42
High	4 (10.0)	15 (15.2)
KPS
≤80	18 (45.0)	33 (14.9)	0.21
>80	22 (55.0)	65 (85.1)
Grade group
G1–G2	14 (37.5)	47 (21.2)	0.21
G3–G4	26 (62.5)	52 (78.8)
Stage at therapy start
Locally advanced	7 (17.5)	17 (17.2)	0.96
Metastatic	33 (82.5)	82 (82.8)